Scientists at King’s College London have identified an experimental drug that helped repair broken DNA and reduced brain inflammation in a mouse model of Alzheimer’s disease, and that has already completed Phase 1 human safety and tolerability trials in the course of its earlier development. The drug, KCL-286, targets several processes linked to the disease at once, unlike treatments that focus primarily on protein buildup. Its effectiveness against Alzheimer’s in humans has not been established, and the new findings remain preclinical.
The research suggests KCL-286, a small molecule that can be taken by mouth, may help repair damaged DNA, reduce inflammation and act on biological changes associated with Alzheimer’s disease. It was originally developed for spinal cord injuries, and earlier work by the same King’s College London team found molecular pathways shared by acute spinal cord injury and Alzheimer’s disease, which led the researchers to test whether a drug aimed at nervous system damage might also affect Alzheimer’s-related changes in neurons.
Much of the effort to develop Alzheimer’s treatments has concentrated on two proteins, amyloid-beta, which can collect into sticky deposits between nerve cells, and tau, which can form tangles inside them. Medications that remove amyloid-beta have shown modest but measurable clinical benefits, but they do not fully address the many biological processes involved in the disease. DNA damage and inflammation in the brain can both appear early in its progression, making them potential targets for treatments designed to slow it.
In the new study, KCL-286 helped repair breaks in DNA and reduced inflammation in mice with Alzheimer's-like disease. The drug works by activating a protein in the retinoic acid pathway, a biological system associated with how the body processes and uses vitamin A. Earlier research found that disruptions in this pathway were associated with the formation of amyloid-beta deposits in the brains of rats. The drug had also previously been shown to promote repair of DNA double-strand breaks in research involving neuropathic pain.
Professor Jonathan Corcoran, Professor of Neuroscience at the Institute of Psychiatry, Psychology & Neuroscience at King's College London, said KCL-286 had already successfully cleared Phase 1 human safety and tolerability trials, which he said "will dramatically cut down the traditional multi-year timeline required for new drug development." He described double-strand breaks, in which both strands of the DNA molecule are severed, as being "like a rope snapping completely in two, rather than just fraying at the edges," and said the team found the drug promotes repair of these breaks.
Dr Maria Goncalves, who project-managed the drug development, said the findings demonstrate that KCL-286 "not only targets DNA damage but also reduces inflammation, two processes that occur very early in Alzheimer's disease progression," which she said highlights its potential as a disease-modifying therapy rather than simply addressing symptoms.
Natasha Hill, one of the first authors on the paper, said that to develop an effective treatment for Alzheimer's disease, multiple aspects of the disease need to be tackled, and that KCL-286 was able to target multiple disease-relevant cellular pathways, some of which are initiated very early in the disease course.
The researchers say the Alzheimer’s findings remain preclinical, and that additional studies and human clinical trials will be necessary to determine whether the drug can safely slow disease progression or improve outcomes in patients. The drug can be taken by mouth, making it potentially more convenient to administer than treatments that require injections or infusions.
Analysis
Why This Matters
- The approach shifts attention from amyloid-beta and tau alone to DNA repair and inflammation, processes the researchers say begin early in Alzheimer's, which could open a different route to slowing the disease rather than treating symptoms.
- Because KCL-286 has already been through Phase 1 safety and tolerability testing in earlier development, it may reach further trials faster than a wholly new compound, provided regulators and funders accept that earlier data.
- For patients and families, nothing changes yet: the results come from mice, and whether the drug helps people with Alzheimer's is untested.
Background
Alzheimer's disease is the most common cause of dementia and involves a complicated series of changes in the brain, including the accumulation of abnormal proteins, the loss of neurons and, as this research highlights, DNA damage and inflammation. For years the main drug-development effort has centred on removing amyloid-beta, and treatments that do so have produced modest but measurable clinical benefits without halting the disease. Researchers have increasingly looked at other processes that appear early in its course, on the reasoning that attacking several at once may be more effective than targeting one. King's College London's interest in KCL-286 came from its earlier work on spinal cord injury, where the same compound was found to promote DNA repair.
Key Perspectives
Professor Jonathan Corcoran, King's College London: says KCL-286 is a first-in-class, orally bioavailable small molecule that has already cleared Phase 1 human safety and tolerability trials, which will dramatically cut down the traditional multi-year timeline for new drug development.
Dr Maria Goncalves, who project-managed the drug development: says the findings show the drug targets both DNA damage and inflammation, processes that occur very early in Alzheimer's progression, highlighting its potential as a disease-modifying therapy rather than simply addressing symptoms.
Natasha Hill, first author: says an effective Alzheimer's treatment needs to tackle multiple aspects of the disease, and that KCL-286 targeted multiple disease-relevant cellular pathways, some initiated very early in the disease course.
What to Watch
- Whether the team publishes full peer-reviewed results and moves KCL-286 into Phase 2 trials in people with Alzheimer's disease.
- How regulators treat the existing Phase 1 safety and tolerability data from the drug's earlier development when future trials are designed.
- Any evidence from further animal work on whether the DNA repair and anti-inflammatory effects translate into slower cognitive decline, not just changes in biological markers.
Checked
12 claims in this story checked against 1 source: 11 supported.
Show each claim
- SupportedKCL-286 helped repair DNA damage and reduce brain inflammation in an Alzheimer’s-like mouse model.Latest Science News -- ScienceDaily: “In the new study, KCL-286 helped repair breaks in DNA and reduce inflammation in mice with Alzheimer's-like disease.”
- SupportedKCL-286 was originally developed for spinal cord injuries.Latest Science News -- ScienceDaily: “Their research suggests that an experimental drug originally developed for spinal cord injuries may help repair damaged DNA, reduce inflammation, and target biological changes associated with the disease.”
- SupportedKCL-286 completed Phase 1 human safety and tolerability trials during its earlier development.Latest Science News -- ScienceDaily: “One particularly promising advantage is that KCL-286 has already completed Phase 1 human safety and tolerability trials as part of its earlier development.”
- SupportedKCL-286’s effect against Alzheimer’s in people has not been established.Latest Science News -- ScienceDaily: “This could significantly shorten the path toward further clinical testing, although its effectiveness against Alzheimer's in humans has not yet been established.”
- SupportedProfessor Jonathan Corcoran said KCL-286 had cleared Phase 1 safety and tolerability trials and that this would dramatically cut the traditional drug-development timeline.Latest Science News -- ScienceDaily: “"KCL-286 is a first-in-class, orally bioavailable small molecule that has already successfully cleared Phase 1 human safety and tolerability trials. This will dramatically cut down the traditional multi-year timeline required for new drug development," commented Professor Jonathan Corcoran”
- SupportedCorcoran compared DNA double-strand breaks to a rope snapping completely in two, and said KCL-286 promotes repair of these breaks.Latest Science News -- ScienceDaily: “"DNA double-strand breaks are like a rope snapping completely in two, rather than just fraying at the edges. We found that KCL-286 promotes repair of these breaks”
- SupportedMaria Goncalves said KCL-286 targets DNA damage and reduces inflammation, processes that occur very early in Alzheimer’s progression, highlighting its potential as a disease-modifying therapy.Latest Science News -- ScienceDaily: “"Our findings demonstrate that KCL-286 not only targets DNA damage but also reduces inflammation, two processes that occur very early in Alzheimer's disease progression. This highlights its potential as a disease-modifying therapy rather than simply addressing symptoms," said Dr. Maria Goncalves”
- SupportedEarlier work by the same King’s College London team found pathways shared by spinal cord injury and Alzheimer’s, leading scientists to investigate whether the drug might also affect Alzheimer’s-related changes.Latest Science News -- ScienceDaily: “Previous work by the same team at King's College London identified molecular pathways shared by acute spinal cord injury and Alzheimer's disease. Because the two conditions involve some overlapping biological mechanisms, the scientists believed that a drug developed to address nervous system damage after spinal cord injury might also improve certain Alzheimer's-related changes in neurons.”
- SupportedKCL-286 works by activating a protein in the retinoic acid pathway.Latest Science News -- ScienceDaily: “The drug works by activating a particular protein involved in the retinoic acid pathway, a biological system associated with how the body processes and uses vitamin A.”
- SupportedEarlier research linked disruptions in the retinoic acid pathway with amyloid-beta deposits in rat brains.Latest Science News -- ScienceDaily: “Earlier research found that disruptions in this pathway were associated with the formation of amyloid-beta deposits in the brains of rats.”
- Partly supportedThe researchers say the Alzheimer’s findings remain preclinical and further studies and human trials are needed to assess safety and patient outcomes.Latest Science News -- ScienceDaily: “However, the Alzheimer's findings remain preclinical. Additional studies and human clinical trials will be necessary to determine whether the drug can safely slow disease progression or improve outcomes in patients.”
- SupportedNatasha Hill said KCL-286 targeted multiple disease-relevant cellular pathways, some initiated very early in the disease course.Latest Science News -- ScienceDaily: “KCL-286 was able to target multiple disease-relevant cellular pathways, some of which are initiated very early in the disease course.”
